These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

237 related items for PubMed ID: 30963682

  • 1. The fraction of CD117/c-KIT-expressing erythroid precursors predicts ESA response in low-risk myelodysplastic syndromes.
    Raimbault A, Itzykson R, Willems L, Rousseau A, Chapuis N, Mathis S, Clauser S, Radford-Weiss I, Bouscary D, Fontenay M, Kosmider O, Bardet V.
    Cytometry B Clin Cytom; 2019 May; 96(3):215-222. PubMed ID: 30963682
    [Abstract] [Full Text] [Related]

  • 2. Erythropoiesis in myelodysplastic syndrome: expression of receptors for erythropoietin and kit ligand.
    Backx B, Broeders L, Hoefsloot LH, Wognum B, Löwenberg B.
    Leukemia; 1996 Mar; 10(3):466-72. PubMed ID: 8642863
    [Abstract] [Full Text] [Related]

  • 3. Dyserythropoiesis evaluated by the RED score and hepcidin:ferritin ratio predicts response to erythropoietin in lower-risk myelodysplastic syndromes.
    Park S, Kosmider O, Maloisel F, Drenou B, Chapuis N, Lefebvre T, Karim Z, Puy H, Alary AS, Ducamp S, Verdier F, Bouilloux C, Rousseau A, Jacob MC, Debliquis A, Charpentier A, Gyan E, Anglaret B, Leyronnas C, Corm S, Slama B, Cheze S, Laribi K, Amé S, Rose C, Lachenal F, Toma A, Pica GM, Carre M, Garban F, Mariette C, Cahn JY, Meunier M, Herault O, Fenaux P, Wagner-Ballon O, Bardet V, Dreyfus F, Fontenay M.
    Haematologica; 2019 Mar; 104(3):497-504. PubMed ID: 30287621
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Transforming growth factor-β superfamily ligand trap ACE-536 corrects anemia by promoting late-stage erythropoiesis.
    Suragani RN, Cadena SM, Cawley SM, Sako D, Mitchell D, Li R, Davies MV, Alexander MJ, Devine M, Loveday KS, Underwood KW, Grinberg AV, Quisel JD, Chopra R, Pearsall RS, Seehra J, Kumar R.
    Nat Med; 2014 Apr; 20(4):408-14. PubMed ID: 24658078
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Prediction of Response to Erythropoiesis Stimulating Agents in Low-Risk Myelodysplastic Syndromes.
    Hattakitpanitchakul S, Kobbuaklee S, Wudhikarn K, Polprasert C.
    Asian Pac J Cancer Prev; 2021 Dec 01; 22(12):4037-4042. PubMed ID: 34967586
    [Abstract] [Full Text] [Related]

  • 9. Expression of CD44 and CD35 during normal and myelodysplastic erythropoiesis.
    Laranjeira P, Rodrigues R, Carvalheiro T, Constanço C, Vitória H, Matarraz S, Trindade H, Órfão A, Paiva A.
    Leuk Res; 2015 Mar 01; 39(3):361-70. PubMed ID: 25582385
    [Abstract] [Full Text] [Related]

  • 10. An optimized system for studies of EPO-dependent murine pro-erythroblast development.
    Zhang D, Johnson MM, Miller CP, Pircher TJ, Geiger JN, Wojchowski DM.
    Exp Hematol; 2001 Nov 01; 29(11):1278-88. PubMed ID: 11698123
    [Abstract] [Full Text] [Related]

  • 11. Lenalidomide with or without erythropoietin in transfusion-dependent erythropoiesis-stimulating agent-refractory lower-risk MDS without 5q deletion.
    Toma A, Kosmider O, Chevret S, Delaunay J, Stamatoullas A, Rose C, Beyne-Rauzy O, Banos A, Guerci-Bresler A, Wickenhauser S, Caillot D, Laribi K, De Renzis B, Bordessoule D, Gardin C, Slama B, Sanhes L, Gruson B, Cony-Makhoul P, Chouffi B, Salanoubat C, Benramdane R, Legros L, Wattel E, Tertian G, Bouabdallah K, Guilhot F, Taksin AL, Cheze S, Maloum K, Nimuboma S, Soussain C, Isnard F, Gyan E, Petit R, Lejeune J, Sardnal V, Renneville A, Preudhomme C, Fontenay M, Fenaux P, Dreyfus F.
    Leukemia; 2016 Apr 01; 30(4):897-905. PubMed ID: 26500139
    [Abstract] [Full Text] [Related]

  • 12. TET2 deficiency leads to stem cell factor-dependent clonal expansion of dysfunctional erythroid progenitors.
    Qu X, Zhang S, Wang S, Wang Y, Li W, Huang Y, Zhao H, Wu X, An C, Guo X, Hale J, Li J, Hillyer CD, Mohandas N, Liu J, Yazdanbakhsh K, Vinchi F, Chen L, Kang Q, An X.
    Blood; 2018 Nov 29; 132(22):2406-2417. PubMed ID: 30254129
    [Abstract] [Full Text] [Related]

  • 13. Increasing the effectiveness of hematopoiesis in myelodysplastic syndromes: erythropoiesis-stimulating agents and transforming growth factor-β superfamily inhibitors.
    Mies A, Platzbecker U.
    Semin Hematol; 2017 Jul 29; 54(3):141-146. PubMed ID: 28958287
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Management of anemia in low-risk myelodysplastic syndromes treated with erythropoiesis-stimulating agents newer and older agents.
    Castelli R, Schiavon R, Rossi V, Deliliers GL.
    Med Oncol; 2018 Apr 19; 35(5):76. PubMed ID: 29675620
    [Abstract] [Full Text] [Related]

  • 19. The myelodysplastic syndromes flow cytometric score: a three-parameter prognostic flow cytometric scoring system.
    Alhan C, Westers TM, Cremers EM, Cali C, Witte BI, Ossenkoppele GJ, van de Loosdrecht AA.
    Leukemia; 2016 Mar 19; 30(3):658-65. PubMed ID: 26503643
    [Abstract] [Full Text] [Related]

  • 20. Early introduction of ESA in low risk MDS patients may delay the need for RBC transfusion: a retrospective analysis on 112 patients.
    Park S, Kelaidi C, Sapena R, Vassilieff D, Beyne-Rauzy O, Coiteux V, Vey N, Ravoet C, Cheze S, Rose C, Legros L, Stamatoullas A, Escoffre-Barbe M, Guerci A, Chaury MP, Fenaux P, Dreyfus F.
    Leuk Res; 2010 Nov 19; 34(11):1430-6. PubMed ID: 20580086
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.